Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Medical treatment of hepatocellular carcinoma.

Germano D, Tinessa V, Barletta E, Cannella L, Daniele B.

Minerva Med. 2013 Oct;104(5):545-61. Review.

PMID:
24101112
2.

Medical therapies for hepatocellular carcinoma: a critical view of the evidence.

Villanueva A, Hernandez-Gea V, Llovet JM.

Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):34-42. doi: 10.1038/nrgastro.2012.199. Epub 2012 Nov 13. Review.

PMID:
23147664
3.

Systemic therapy of hepatocellular carcinoma: current status and future perspectives.

Germano D, Daniele B.

World J Gastroenterol. 2014 Mar 28;20(12):3087-99. doi: 10.3748/wjg.v20.i12.3087. Review.

4.

Emerging targeted strategies in advanced hepatocellular carcinoma.

Finn RS.

Semin Liver Dis. 2013 Feb;33 Suppl 1:S11-9. doi: 10.1055/s-0033-1333632. Epub 2013 Mar 1. Review.

PMID:
23457035
5.

Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?

Lencioni R, Chen XP, Dagher L, Venook AP.

Oncologist. 2010;15 Suppl 4:42-52. doi: 10.1634/theoncologist.2010-S4-42. Review.

6.

Targeted therapy for liver cancer: updated review in 2012.

Kudo M.

Curr Cancer Drug Targets. 2012 Nov 1;12(9):1062-72. Review.

PMID:
22920326
7.

Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.

Kim HY, Park JW.

Dig Dis. 2011;29(3):303-9. doi: 10.1159/000327563. Epub 2011 Aug 9. Review.

PMID:
21829021
8.

Molecularly targeted therapy in hepatocellular carcinoma.

Huynh H.

Biochem Pharmacol. 2010 Sep 1;80(5):550-60. doi: 10.1016/j.bcp.2010.03.034. Epub 2010 Apr 4. Review.

PMID:
20371362
10.

Targeted therapy of hepatocellular cancer.

Wysocki PJ.

Expert Opin Investig Drugs. 2010 Feb;19(2):265-74. doi: 10.1517/13543780903514110. Review.

PMID:
20074016
11.

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Llovet JM, Hernandez-Gea V.

Clin Cancer Res. 2014 Apr 15;20(8):2072-9. doi: 10.1158/1078-0432.CCR-13-0547. Epub 2014 Mar 3. Review.

12.

Advanced HCC: emerging molecular therapies.

Finn RS.

Minerva Gastroenterol Dietol. 2012 Mar;58(1):25-34. Review.

PMID:
22419002
13.

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

Zhu AX.

Expert Opin Investig Drugs. 2010 May;19(5):663-72. doi: 10.1517/13543781003767426. Review.

PMID:
20367287
14.

[The hepatocellular carcinoma: alternative therapeutical strategies].

Spangenberg HC, Thimme R, Mohr L, Blum HE.

Zentralbl Chir. 2007 Aug;132(4):322-7. Review. German.

PMID:
17724635
15.

An update on clinical trials in the treatment of advanced hepatocellular carcinoma.

Lee JK, Abou-Alfa GK.

J Clin Gastroenterol. 2013 Jul;47 Suppl:S16-9. doi: 10.1097/MCG.0b013e31827d77a2.

PMID:
23751800
16.

Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.

Yau T, Pang R, Chan P, Poon RT.

Expert Opin Pharmacother. 2010 Sep;11(13):2187-98. doi: 10.1517/14656561003724705. Review.

PMID:
20707757
17.

Systemic therapy of hepatocellular carcinoma: are we making progress?

Roxburgh P, Evans TR.

Adv Ther. 2008 Nov;25(11):1089-104. doi: 10.1007/s12325-008-0113-z. Review.

PMID:
18972075
18.

Future treatment option for hepatocellular carcinoma: a focus on brivanib.

Kudo M.

Dig Dis. 2011;29(3):316-20. doi: 10.1159/000327568. Epub 2011 Aug 9. Review.

19.

Improved chemotherapy for hepatocellular carcinoma.

Cao H, Phan H, Yang LX.

Anticancer Res. 2012 Apr;32(4):1379-86. Review.

PMID:
22493374
20.

Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.

Frenette C, Gish R.

World J Gastroenterol. 2012 Feb 14;18(6):498-506. doi: 10.3748/wjg.v18.i6.498. Review.

Supplemental Content

Support Center